Table 2

Frequency of citrullinated/mutated antibodies in 1011 patients at baseline, with OR and 95% CIs calculated on controls (n=477) analysed at the laboratory and stratified for antibodies against cyclic citrullinated peptide (anti-CCP2)

Antibody against citrullinated/mutated peptidesFrequency n (%)OR (95% CI)Anti-CCP2 positive (n=680)
n (%)
Anti-CCP2 negative (n=327)
n (%)
αEno5-21 (CEP-1)551 (53.9)60.8 (31.1 to 119.0)523 (76.9)18 (5.5)
CII359-369306 (29.9)22.2 (11.3 to 43.6)290 (42.6)12 (3.7)
F4-R-CIT492 (48.1)17.6 (11.5 to 27.0)463 (68.1)22 (6.7)
F4-CIT-CIT411 (40.2)15.4 (9.7 to 24.5)387 (56.9)18 (5.5)
F4-CIT-R264 (25.8)5.8 (3.9 to 8.8)250 (36.8)9 (2.8)
Fibα36–50263 (15.7)18.0 (9.2 to 35.4)243 (35.7)18 (5.5)
Fibα563–583387 (37.9)35.7 (17.6 to 72.7)376 (55.3)7 (2.1)
Fibα580–600205 (20.1)13.0 (6.6 to 25.7)195 (28.7)9 (2.8)
Fibα621–635398 (38.9)33.2 (16.9 to 65.0)375 (55.1)18 (5.5)
Fibβ36–52562 (55.9)63.5 (32.5 to 124.3)531 (78.1)24 (7.3)
Fibβ62–78 (72)136 (13.3)8.0 (4.0 to 15.8)120 (17.6)12 (3.7)
Fibβ62–78 (74)262 (25.6)18.0 (9.1 to 35.2)248 (36.5)9 (2.8)
Fibβ60–74645 (63.1)89.0 (45.4 to 174.2)608 (89.4)26 (8.0)
Fil307-324 (CCP1)561 (54.9)63.3 (32.3 to 123.8)536 (78.8)17 (5.2)
Vim2-17222 (21.7)14.4 (7.3 to 28.4)208 (30.6)11 (3.4)
Vim60-75578 (56.6)76.2 (37.5 to 154.9)551 (81.0)19 (5.8)
Bla-26338 (33.1)23.1 (12.2 to 43.8)315 (46.3)19 (5.8)
Pept-1250 (24.5)21.7 (10.2 to 46.5)238 (35.0)10 (3.1)
Pept-5530 (51.9)56.0 (28.6 to 109.6)500 (73.5)24 (7.3)
PeptZ1480 (47.0)46.1 (23.5 to 90.1)458 (67.4)14 (4.3)
PeptZ2506 (49.5)51.0 (26.1 to 99.7)479 (70.4)20 (6.1)
  • α-Enolase peptide 5-21 (CEP-1), collagen type II (CII359-369, F4-R-CIT, F4-CIT-CIT and F4-CIT-R), fibrinogen (Fib) α36-50, Fibα5673–583, Fibα580-600, Fibα621–635, Fibβ36–52, Fibβ62–78 (72), Fibβ62–78 (74), Fibβ60–74, Filaggrin (Fil307-324), vimentin (Vim) 2-17, Vim60-75 and mutated proteins (Bla26, Pept-1, Pept-5, PeptZ1 and PeptZ2).